The prognostic role of early tumor shrinkage in patients with hepatocellular carcinoma undergoing immunotherapy

BACKGROUND: Early tumor shrinkage (ETS) has been identified as a promising imaging biomarker for patients undergoing immunotherapy for several cancer entities. This study aimed to validate the potential of ETS as an imaging biomarker for patients undergoing immunotherapy for hepatocellular carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Lukas, Gairing, Simon Johannes, Kloeckner, Roman, Foerster, Friedrich, Schleicher, Eva Maria, Weinmann, Arndt, Mittler, Jens, Stoehr, Fabian, Halfmann, Moritz Christian, Düber, Christoph, Galle, Peter Robert, Hahn, Felix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509639/
https://www.ncbi.nlm.nih.gov/pubmed/36153569
http://dx.doi.org/10.1186/s40644-022-00487-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509639/
https://www.ncbi.nlm.nih.gov/pubmed/36153569
http://dx.doi.org/10.1186/s40644-022-00487-x

Ejemplares similares